Cargando…

Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma

Treatment for endometrial cancer is rapidly evolving with the increased use and integration of somatic tumor RNA sequencing in clinical practice. There is a paucity of data regarding PARP inhibition in endometrial cancer given that mutations in homologous recombination genes are rare, and currently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Senguttuvan, Rosemary Noel, Wei, Christina, Raoof, Mustafa, Dellinger, Thanh H., Wang, Edward Wenge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253277/ https://www.ncbi.nlm.nih.gov/pubmed/37298034 http://dx.doi.org/10.3390/jcm12113839

Ejemplares similares

Complete Clinical Response in Stage IVB Endometrioid Endometrial Carcinoma after First-Line Pembrolizumab Therapy: Report of a Case with Isolated Loss of PMS2 Protein
por: Carvalho, Jesus Paula, et al.
Publicado: (2020)

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
por: Bian, X, et al.
Publicado: (2018)

Circulating microRNAs as a Fingerprint for Endometrial Endometrioid Adenocarcinoma
por: Wang, Lin, et al.
Publicado: (2014)

An Unusual Solitary Metatarsal Metastasis from an Endometrioid Endometrial Adenocarcinoma
por: Longo, Raffaele, et al.
Publicado: (2015)

ASO Author Reflections: Preventing Nephrotoxicities in Ovarian Cancer Patients Undergoing HIPEC
por: Senguttuvan, Rosemary N., et al.
Publicado: (2023)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

Endometrioid endometrial adenocarcinoma in a premenopausal woman with multiple organ metastases
por: Srikantia, Nirmala, et al.
Publicado: (2009)

Metabotyping human endometrioid endometrial adenocarcinoma reveals an implication of endocannabinoid metabolism
por: Jové, Mariona, et al.
Publicado: (2016)

RRBP1 overexpression is associated with progression and prognosis in endometrial endometrioid adenocarcinoma
por: Liu, Shuang, et al.
Publicado: (2019)

The analysis of hormonal status and vascular and cell proliferation in endometrioid endometrial adenocarcinomas
por: Drocaş, Ileana, et al.
Publicado: (2022)

Outcomes of Patients With Surgically and Pathologically Staged IIIA-IVB Pure Endometrioid-type Endometrial Cancer: A Taiwanese Gynecology Oncology Group (TGOG–2005) Retrospective Cohort Study (A STROBE-Compliant Article)
por: Chen, Jen-Ruei, et al.
Publicado: (2016)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

An integrated prediction model of recurrence in endometrial endometrioid cancers
por: Miller, Marina D, et al.
Publicado: (2019)

Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
por: Gross, Maya, et al.
Publicado: (2022)

Endometriosis-associated endometrioid adenocarcinoma of the fallopian tube synchronized with endometrial adenocarcinoma: A case report
por: Feng, Jian-Yang, et al.
Publicado: (2023)

Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis
por: Davidson, Brittany A., et al.
Publicado: (2016)

Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma
por: SATO, MASAKAZU, et al.
Publicado: (2016)

Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
por: Miyasaka, Aki, et al.
Publicado: (2014)

Optimal Management for Stage IVB Endometrial Cancer: A Systematic Review
por: Capozzi, Vito Andrea, et al.
Publicado: (2023)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019)

Hypoxia and Angiogenesis in Endometrioid Endometrial Carcinogenesis
por: Horrée, Nicole, et al.
Publicado: (2007)

VEGF Immunoexpression in Endometrioid Endometrial Carcinomas
por: DROCAŞ, ILEANA, et al.
Publicado: (2022)

Snail Immunoexpression in Endometrioid Endometrial Carcinomas
por: FLORESCU, MIRELA MARINELA, et al.
Publicado: (2022)

Effectiveness of Megestrol for the Treatment of Patients with Atypical Endometrial Hyperplasia or Endometrial Endometrioid Adenocarcinoma (Stage IA, Well Differentiated)
por: Akhavan, Setareh, et al.
Publicado: (2021)

Concomitant endometrioid carcinoma of the ovary and endometrial carcinoma of the uterus associated with adenocarcinoma in situ of the cervix.
por: Parker, M., et al.
Publicado: (1989)

Look at This Swelling: Retroauricular Mass as Atypical Progression in Long-Survivor Endometrial Endometrioid Adenocarcinoma
por: De Felice, Marco, et al.
Publicado: (2023)

Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report
por: Taguchi, Tomomi, et al.
Publicado: (2022)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
por: Osoegawa, Atsushi, et al.
Publicado: (2017)

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2017)

Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
por: Voorneveld, Jim, et al.
Publicado: (2020)

PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
por: Liu, Chuan, et al.
Publicado: (2020)

Synchronous Ovarian and Endometrial Endometrioid Adenocarcinoma Presenting with Nonbacterial Thrombotic Endocarditis and Pulmonary Thromboembolism: Adenocarcinoma with Thrombotic Events
por: Erturk, N. K., et al.
Publicado: (2015)

Clinicopathological Prognostic Parameters of Endometrioid Endometrial Carcinomas
por: DROCAŞ, ILEANA, et al.
Publicado: (2022)

Endometrioid adenocarcinoma associated with endometrial stromal sarcoma: A rare, often unrecognized collision tumor
por: Kim, Grace, et al.
Publicado: (2015)

When the endometrioid adenocarcinoma and the endometrial stromal sarcoma meet: A report of an extremely rare case
por: Koutras, Antonios, et al.
Publicado: (2022)

Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma
por: Veade, Ashley E., et al.
Publicado: (2019)

Role of serum microRNAs as biomarkers for endometriosis, endometrioid carcinoma of ovary & endometrioid endometrial cancer
por: Kumari, Priti, et al.
Publicado: (2022)

Rapid identification of endometrial hyperplasia and endometrial endometrioid cancer in young women
por: Kuai, Dan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v0alvokfppadg98r9f5i20qe3o